ReviewProgress in cardiovascular diseases
Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines.
Review in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Treatment Intensity, Prescribing Patterns, and Blood Pressure Control in Rural Black Patients with Uncontrolled Hypertension.Journal of racial and ethnic health disparities · 2023Trial
- Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Community Clinic Blood Pressure and BMI Control in Black Americans with Hypertension: A Retrospective Chart Review.Journal of racial and ethnic health disparities · 2026Article
- Disparities in Initial Antihypertensive Intensity by Sex, Race and Ethnicity in Newly Treated Patients With Hypertension.American journal of hypertension · 2025Article
- Hypertension in Sub-Saharan Africa: Burden, Barriers and Priorities for Improving Treatment Outcomes.Circulation research · 2025Review
- Launching Financial Incentives for Physician Groups to Improve Equity of Care by Patient Race and Ethnicity.The Milbank quarterly · 2024Article
- Seven Strategies to Integrate Equity within Translational Research in Neurology.Annals of neurology · 2024Review
- Effects of Part D Star Ratings on racial and ethnic disparities in health care costs.Exploratory research in clinical and social pharmacy · 2023Article
- The Self-Fulfilling Process of Clinical Race Correction: The Case of Eighth Joint National Committee Recommendations.Health equity · 2023Article
- Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity.Healthcare (Basel, Switzerland) · 2022Review
- Examining the Inclusion of Race and Ethnicity in Patient Cases.American journal of pharmaceutical education · 2021Article
- Disease Expression and Outcomes in Black and White Adults With Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2021Article
- Prevalence of Chronic Kidney Disease as a Marker of Hypertension Target Organ Damage in Africa: A Systematic Review and Meta-Analysis.International journal of hypertension · 2021Review
- Why is COVID-19 especially impacting the African American population?Annals of medicine · 2020Article
- Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study.Hypertension (Dallas, Tex. : 1979) · 2020Article
- The Influence of Discrimination and Coping Style on Blood Pressure Among Black/African American Women in the InterGEN Study.Health equity · 2020Article
- Traditional Chinese Patent Medicine for Primary Hypertension: A Bayesian Network Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure.Health equity · 2019Article
- Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Article
- Differences in Hypertension Medication Prescribing for Black Americans and Their Association with Hypertension Outcomes.Journal of the American Board of Family Medicine : JABFMObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Blacks are especially susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular, cerebrovascular and renal outcomes. Accordingly, HTN is particularly significant in contributing to the black-white racial differences in health outcomes in the US. As such, in order to address these health disparities, practical clinical practice guidelines (CPGs) on how to treat HTN, specifically in blacks, are needed. This review article is a timely addition to the literature because the most recent U.S. CPG more explicitly emphasizes race into the algorithmic management of HTN. However, recent clinical research cautions that use of race as a proxy to determine therapeutic response to pharmaceutical agents may be erroneous. This review will address the implications of the use of race in the hypertension CPGs. We will review the rationale behind the introduction of race into the U.S. CPG and the level of evidence that was available to justify this introduction. Finally, we will conclude with practical considerations in the treatment of HTN in blacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.